Revolutionizing AAV Vector Production

Listen to the Free Accessible Webinar of Dr. Nicole Faust, CEO & CSO, CEVEC

Cell & Gene Therapy ManufacturingDigital Week – April 10, 2018

Upscaling GMP production of viral vectors is currently one of the big technical challenges in gene therapies. CEVEC has developed the fully scalable CAP-GT platform, based on serum-free suspension cells which can efficiently produce lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV) vectors at industrial scale. The session will focus on the newly developed AAV packaging system, allowing the helper virus-free stable production of AAV vectors without the need of a transient transfection step.

Contact:
CEVEC Pharmaceuticals GmbH
Dr. Nicole Faust, CEO & CSO
E-mail: 
bizdev@cevec.com